The evidence base for plasma transfusion in neonatal sepsis remains unsettled, with a review highlighting promising theory but conflicting clinical data. The article frames plasma therapy as a potential immunologic or supportive strategy, while emphasizing the lack of consistent benefit signals. For neonatal intensive care units, this uncertainty affects protocol design and how clinicians weigh risks such as transfusion-related complications against suspected benefits. The immediate industry impact is operational: teams may continue to treat plasma selectively while awaiting higher-quality, more definitive trial outcomes.